AI just flipped vaccine development on its head. The University of Cambridge tested a vaccine using an antigen designed entirely by artificial intelligence. This isn’t your typical reactive jab. The AI-created “super-antigen” aims to protect against a broad range of Sarbeco coronaviruses, including SARS-CoV-2 and related bat viruses lurking on the horizon.

Thirty-nine healthy volunteers aged 18 to 50 took part in early trials across two UK sites. The vaccine sparked a protective immune response without notable side effects. Unlike traditional vaccines that chase virus mutations like a dog chasing its tail, this one anticipates future variants by targeting common viral features. It promises long-term, broad-spectrum defense not just against COVID but potentially against flu, Ebola, and other zoonotic threats.

Cambridge researchers fed the AI model extensive global viral genetic data. Machine learning then engineered an antigen combining elements common to the entire Sarbeco family. This strategy could eliminate the endless vaccine updates we’ve grown used to. According to Professor Jonathan Heeney, this approach shifts vaccine development from reactive to future-proof.

Meanwhile, Oxford University is racing on a different front: personalized cancer vaccines. Backed by fresh funding and access to the DAWN supercomputer, their team uses AI platforms like CIARA to decode tumor biology and design mRNA vaccines tailored to individual patients. This project involves over 2,500 experts blending AI, medicine, and manufacturing.

Oxford’s AI-driven system analyzes vast cancer and immune datasets far beyond typical university computing limits. The goal is to identify precise vaccine targets that stimulate a potent immune attack on tumors. Early phases include manufacturing experimental mRNA vaccines and testing AI predictions in patient samples. Dr. Lennard Lee, project lead, says UK sovereign AI systems now speed the transition from prediction to personalized drug development.

AI Accelerates Ebola Vaccine Development Amid Ongoing Outbreak

While Cambridge and Oxford push boundaries in coronaviruses and cancer, Oxford researchers also fast-track an Ebola vaccine targeting the Bundibugyo strain ravaging the Democratic Republic of Congo. Existing vaccines cover only the Zaire strain, leaving this outbreak unprotected. Using the viral-vector platform behind the Oxford-AstraZeneca COVID vaccine, scientists adapt it for the Bundibugyo virus.

This effort received rapid funding from the Coalition for Epidemic Preparedness Innovations in June 2026. The team runs pre-clinical animal tests and simultaneously manufactures vaccine batches for human trials. Their approach leverages platform technology knowledge to compress timelines. The challenge isn’t creating Ebola vaccines—it’s having them ready when outbreaks occur. Oxford’s model aims to sidestep delays that cost lives.

Across these projects, AI isn’t just speeding up research. It’s changing the rules. Designing antigens and vaccines with AI lets scientists anticipate viral mutations, personalize cancer treatments, and prepare for emerging epidemics faster than ever. The UK’s sovereign AI infrastructure proves critical, enabling data crunching at unprecedented scale. This isn’t science fiction. It’s the new normal for biotech innovation.